Treatment Options for Plaque Psoriasis: Effectiveness and Value

Voting Questions for November 18, 2016 Public Meeting

These questions are intended for the deliberation of the New England CEPAC voting body at the public meeting.

**Patient population for all voting questions:** Patients with moderate-to-severe plaque psoriasis for whom treatment with topical therapies, older systemic therapies, and/or phototherapy has been ineffective, contraindicated, or not tolerated.

**Comparator for all voting questions unless specified otherwise:** continued untargeted therapy.

1) Is the evidence adequate to demonstrate that the net health benefit of apremilast is as good as that provided by any of the TNF-α inhibitors?
   
   Yes    No

2) Is the evidence adequate to distinguish the net health benefit among the IL-17A targeted drugs secukinumab, ixekizumab, and brodalumab?
   
   Yes    No

   If no...
   
   a. Is the evidence adequate to demonstrate that the net health benefit of [IL-17A drugs as a class] is better than that provided by adalimumab?
      
      Yes    No

   b. Is the evidence adequate to demonstrate that the net health benefit of [IL-17A drugs as a class] is better than that provided by etanercept?
      
      Yes    No

   c. Is the evidence adequate to demonstrate that the net health benefit of [IL-17A drugs as a class] is better than that provided by infliximab?
      
      Yes    No
3) Is the evidence adequate to demonstrate that the net health benefit of ustekinumab is better than that provided by adalimumab?

Yes  No

4) Is the evidence adequate to demonstrate that the net health benefit of ustekinumab is better than that provided by etanercept?

Yes  No

5) Is the evidence adequate to demonstrate that the net health benefit of ustekinumab is better than that provided by infliximab?

Yes  No

6) Given the available evidence on comparative effectiveness and incremental cost-effectiveness using estimated discounted prices for private insurers presented in the report, and taking into account other benefits, disadvantages, and contextual considerations, what is the long-term value for money of the following drugs compared to continued untargeted therapy?

   Adalimumab
   Etanercept
   Infliximab
   Ustekinumab
   Secukinumab
   Ixekizumab
   Brodalumab
   Apremilast

   a. High  b. Intermediate  c. Low

7) Given the available evidence on comparative clinical effectiveness and incremental cost-effectiveness, and taking into account other benefits, disadvantages, and contextual considerations, what is the long-term value for money of treatment with [any IL-17A drug] versus etanercept?

   a. High  b. Intermediate  c. Low